



**HAL**  
open science

## **SARS-CoV-2 viral dynamics in infections with variants of concern in the French community**

Gina Cosentino, Mathieu Bernard, Joëvin Ambroise, Jean-Marc Giannoli, Jérémie Guedj, Florence Débarre, François Blanquart

► **To cite this version:**

Gina Cosentino, Mathieu Bernard, Joëvin Ambroise, Jean-Marc Giannoli, Jérémie Guedj, et al.. SARS-CoV-2 viral dynamics in infections with variants of concern in the French community. 2021. hal-03217231

**HAL Id: hal-03217231**

**<https://hal.sorbonne-universite.fr/hal-03217231>**

Preprint submitted on 4 May 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# **SARS-CoV-2 viral dynamics in infections with variants of concern in the French community**

Gina Cosentino<sup>1,2</sup>

Mathieu Bernard<sup>3</sup>

Joëvin Ambroise<sup>4</sup>

Jean-Marc Giannoli<sup>5</sup>

Jérémie Guedj<sup>6</sup>

Florence Débarre<sup>7\*</sup>

François Blanquart<sup>6,8\*</sup>

1. BPO-BIOEPINE- Biogroup - Plateau technique Chocolaterie, Levallois-Perret, France
2. UMR1173 INSERM, Université Paris-Saclay - UVSQ, Montigny-le-Bretonneux, France
3. BIOLITTORAL-Biogroup - Plateau technique la Bastide, Sanary sur Mer, France
4. BPO-BIOEPINE- Biogroup - Plateau technique Chocolaterie, Levallois-Perret, France
5. DYOMEDEA-NEOLAB-Biogroup-Plateau technique de la Sauvegarde, Lyon 9 France
6. Infection Antimicrobials Modelling Evolution, UMR 1137, INSERM, Université de Paris, Paris, France
7. Institute of Ecology and Environmental Sciences of Paris (iEES-Paris, UMR 7618), Sorbonne Université, CNRS, UPEC, IRD, INRAE, 75252 Paris, France
8. Centre for Interdisciplinary Research in Biology (CIRB), Collège de France, CNRS, INSERM, PSL Research University, Paris, France

\* equal contributions in supervision

## **Correspondence:**

François Blanquart  
francois.blanquart@college-de-france.fr  
Collège de France  
11 place Marcelin Berthelot F-75005 PARIS  
T. +33 1 44 27 13 79

## **Abstract**

We analysed 871,604 PCR tests performed in the community in the Paris area (France) from 1st January 2021 to 24th March 2021. The PCR cycle threshold (Ct) at symptom onset was  $-1.33$  (95% CI [-1.59, -1.07]) and  $-1.15$  (95% CI [-1.57, -0.697]) lower for individuals infected with B.1.1.7 and B.1.351 compared to other strains. The mean duration of infectiousness after symptom onset (time to Ct > 31) was 8.6, 9.3, 8.9 days for individuals infected with historical strains, variants B.1.1.7 and B.1.351. This study clarifies the post-symptom intra-host dynamics of B.1.1.7 and B.1.351 and suggests that higher peak viral load for these variants may explain part of their evolutionary advantage and the greater pathogenicity of B.1.1.7.

## **Introduction**

Several genetic variants of SARS-CoV-2 with potentially concerning phenotypic consequences were identified at the end of 2020. The B.1.1.7 variant of SARS-CoV-2 (also called VOC-202012/01 or 501Y.V1), first detected in England in September 2020, rapidly rose in frequency in October 2020 in the United Kingdom and spread in multiple countries (1–5). Viruses of this lineage are 50% to 100% more transmissible, have a 60% higher infection fatality ratio (6–8), confer a higher viral load (9–12) and may cause longer infection (10,13). Less is known of the variant B.1.351 / 501Y.V2, which was first detected in South Africa, and also appears more transmissible or able to escape existing immunity and to confer a higher viral load (12,14). Studying intra-host dynamics in a large number of individuals is important (i) to understand pathogenesis and the link between viral load dynamics and disease severity, (ii) to determine if variants of concern are associated to higher viral loads that could lead to greater transmissibility, and (iii) to adapt if necessary the duration of isolation of infected individuals. We used data from 871,604 PCR tests conducted by a large private clinical laboratory in the community in the Ile-de-France region of France from 1st January to 24th March 2021 (17% of all tests in this period). We compared the within-host dynamics of viral load in symptomatic individuals infected by suspected variants of concern B.1.1.7 and B.1.351 to other strains.

## **Methods**

Starting from all tests, negative and positive ( $N = 871,604$ ), we retained 16,134 tests conducted on 12,858 symptomatic individuals for the main analysis. These include all individuals with at least one positive test and associated data on Ct value, sex, age, variant and PCR method (Table 1, Supplementary Figure 1).

We conducted all analyses on the Ct value combining the two Ct values obtained with two primers targeting the RNA-dependent RNA polymerase (RdRp) gene, the most sensitive assays. Both Ct values were highly correlated with a regression coefficient close to 1. All Ct values above 36 were set to undetectable. Individuals are considered infectious below  $Ct = 31$ . When two Ct values were present at the same time point and detectable, we used the mean of the two values. When only one of the two Ct values was present or detectable, we used it and ignored the other. If both Ct values were undetectable, we set the Ct to undetectable.

Variants were detected using two PCRs targeted at the spike deletion 69-70 and at the spike substitution N501Y (IDTM SARS-CoV-2/UK/SA Variant Triplex). Combination of del69-70 and substitution N501Y was interpreted as suspicion of the B.1.1.7 variant. Substitution N501Y

without del69-70 was interpreted as suspicion of the B.1.351 variant. The variant P.1/501Y.V3 was nearly absent in France in the period considered. It was detected in only 10/3429, 9/5472, 41/6592 sequences collected in January, February, March in France according to the GISAID database.

We relied on self-reporting of symptom onset dates. At each test, individuals were asked to declare whether they had symptoms, and what was the date of symptom onset (if any): [0, 3] days ago, [4, 7] days ago, [8, 14] days ago or 15 or more days ago. For individuals with repeated tests, we retained only those for which the timing of symptoms declared at the different visits were consistent with an error margin of two days. For each individual with consistent declarations, we set the time of symptoms to the mean of the earliest possible date and the latest possible date of symptoms.

The censored mixed-effects linear regression describing Ct value as a function of time since symptoms and other covariates was conducted within the R package *lme4*, developed to analyse viral load data truncated at the detection limit of the assay (15). The method treats the viral loads as right-censored (at Ct=36) and infers the maximum likelihood parameters with an expectation-maximization algorithm. We used a normal random effect to represent inter-individual variability in the intercept (Ct at symptom onset). To select a model, we started from the full linear model predicting viral load as a function of time since symptom onset (continuous variable), variant (historical strains, suspected B.1.1.7, suspected B.1.351), age category (10 categories, 0-9, 10-19, ..., 80-89, 90+ years old), and the three pairwise interactions. We assessed the significance levels of each of the interactions, comparing with likelihood ratio test (LRT) the model without the focal interaction to the full model. We also tested the significance of each of the three main effects by comparing with LRT the model without the focal main effect to the model with the three main effects. Confidence intervals were computed using the multivariate normal distribution of the errors on the fixed effects.

## **Results**

Among the 12,858 individuals, most had one test (N = 10,225), 2,121 individuals had two tests and the rest (N = 512 individuals) had three or more tests (Table 1). From the linear regression, there was no significant interaction for viral load between variant and age ( $p = 0.31$ ) and we therefore present results of the simplified model without this interaction.

The predicted viral load at symptom onset was inferred to be 22.7 Ct on average (95% confidence interval, CI, [22.4 – 23.0]) for historical strains (Supplementary Table 1). The inter-

individual standard deviation in viral load at symptom onset was 2.9, meaning that 95% of symptomatic individuals had a viral load at symptom onset between 28.4 and 17.0. The viral load declined on average at a rate of +0.97 Ct per day [0.93 - 1.0]. The viral load at symptom onset was higher in B.1.1.7 and B.1.351 variants than in historical variants, with a Ct value  $-1.33$  [-1.59, -1.07] and  $-1.15$  [-1.57, -0.697] lower than historical strains for B.1.1.7 and B.1.351 respectively ( $p < 10^{-16}$ ). The viral load of the two variants declined slightly faster than that of the historical strains with an additional decline rate of +0.06 [0.015; 0.10] and +0.095 [0.018; 0.16] per day for B.1.1.7 and B.1.351 respectively ( $p = 0.0004$ ). The duration of shedding was longer for individuals infected by variants: the mean time to a Ct of 31, the limit above which the individual is no longer infectious, was 8.6, 9.3 and 8.9 days for historical strains, B.1.1.7 and B.1.351 (Figure 1B). The mean time to a Ct of 36, the limit above which the virus is fully cleared, was 13.7, 14.2 and 13.6 days for historical strains, B.1.1.7 and B.1.351. There is substantial inter-individual variability around these mean values (Figure 1C). We based most of our analyses on the Ct value of the PCR targeting the RdRp gene, but results were very consistent when analyzing the Ct value of the nucleocapsid gene (N), with an even stronger effect of the variants on viral load at symptom onset (effect sizes  $-1.81$  [-2.32; -1.32] and  $-2.11$  [-2.38; -1.81] for B.1.1.7 and B1.351) (Supplementary Table 2, Supplementary Figure 2).

## Discussion

Both B.1.1.7 and B.1.351 variants conferred a higher viral load at symptom onset. The main strengths of our study are the control for time since symptoms, which improves the comparison between historical strains and variants, and the large number of tests, in particular for both B.1.1.7 and B.1.351 variants.

However, several limitations must be noted. We used data from community testing in Ile-de-France. This ensures a large number of tests, but tests are not done systematically and in a random sample of individuals. The date of symptom onset was self-reported. We excluded individuals with inconsistent symptoms dates, but consistency was impossible to assess for the vast majority of individuals with a single test. To address some of these limitations, we ran the same analysis on the more complete dataset where the time from symptom onset was not necessarily known (41,489 tests representing 33,391 individuals), and considered the time since first positive test instead of the self-reported time since symptom onset. Results were very consistent with those of the main analysis (Supplementary Table 3). In addition, individuals declaring symptoms at all their tests had a larger viral load than asymptomatic individuals

( $-0.95$ , CI [ $-1.1$ ,  $-0.83$ ]). A last limitation is that variant assignation is based on PCR screening. The suspected B.1.1.7 and B.1.351 were not confirmed by whole genome sequencing. In Ile-de-France, whole-genome sequencing of a random subset of 609 cases on March 2nd 2021 quantified the prevalence of B.1.1.7 at 76% of interpretable sequences (16). Thus the vast majority of viruses with substitution N501Y and spike deletion 69-70 must be B.1.1.7, as observed in the United Kingdom when the prevalence of B.1.1.7 was substantial (1). The prevalence of B.1.351 in France was 6.5%, and the prevalence of P.1 (first detected in Japan in travelers from Brazil) was 0.3% (16). If only clades B.1.351 and P.1 carried N501Y without del69-70, then 96% of the suspected B.1.351 are true B.1.351.

The evidence presented here from thousands of PCR tests can be compared with densely sampled trajectories of seven individuals infected with B.1.1.7 (13). There, individuals infected with B.1.1.7 had a  $-1.2$  Ct higher viral load than those infected with the historical strains, very similar to our estimate of  $-1.33$ . The authors detected a longer time to clearance ( $+1.8$  days) for individuals infected with B.1.1.7. In our case, clearance (time to threshold Ct 36) was also slightly longer for B.1.1.7 ( $+0.49$  days) and exclusively the result of the higher peak viral load.

To conclude, using 16,134 tests representing 12,858 symptomatic individuals tested positive in the community in Ile-de-France region of France from 1st January 2021 to 24th March 2021, we found that infection by suspected B.1.1.7 and B.1.351 variants strongly impacted the viral load at symptom onset at all ages. Higher viral load could partly explain the greater pathogenicity of B.1.1.7. It could also explain the selective advantage of B.1.1.7 through a transmission advantage (17). Individuals infected by suspected B.1.1.7 and B.1.351 excreted virus (Ct  $< 31$ ) for only slightly longer than those infected by historical strains. This does not preclude the possibility that the mean generation time is longer for individuals infected by these strains, as we did not study the pre-symptomatic phase which could also play a role (13). Larger datasets with systematic PCR tests and capturing the pre-symptomatic phase will improve our understanding of infection by SARS-CoV-2 variants of concern and their potential epidemiological consequences.

### **Acknowledgements**

We acknowledge the contributors of the GISAID database listed in Appendix. FB was funded by a Momentum grant from the Centre National de la Recherche Scientifique.

### **Competing interests**

JG has worked as consultant for ROCHE Company.

### **Biographical sketch of first author**

GC is a PhD student working on the exit mechanisms of respiratory syncytial virus in the INSERM U1173 team led by Marie-Anne Rameix-Welti. In parallel to her PhD thesis, she works as a researcher in the scientific committee of the Biogroup laboratory.



## References:


1. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature*. 2021 Mar 25;1–17.
2. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* [Internet]. 2021 Apr 9 [cited 2021 Apr 16];372(6538). Available from: <https://science.sciencemag.org/content/372/6538/eabg3055>
3. Borges V, Sousa C, Menezes L, Gonçalves AM, Picão M, Almeida JP, et al. Tracking SARS-CoV-2 VOC 202012/01 (lineage B. 1.1. 7) dissemination in Portugal: insights from nationwide RT-PCR Spike gene drop out data. *Virology*. 2021;
4. Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ET, Schiabor Barrett KM, et al. Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. *Cell* [Internet]. 2021 Mar 30 [cited 2021 Apr 16]; Available from: <https://www.sciencedirect.com/science/article/pii/S0092867421003834>
5. Gaymard A, Bosetti P, Feri A, Destras G, Enouf V, Andronico A, et al. Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021. *Eurosurveillance*. 2021 Mar 4;26(9):2100133.
6. Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. *Nature*. 2021 Mar 15;1–5.
7. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. *BMJ*. 2021 Mar 10;372:n579.
8. Grint DJ, Wing K, Williamson E, McDonald HI, Bhaskaran K, Evans D, et al. Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February. *Eurosurveillance*. 2021 Mar 18;26(11):2100256.
9. Kidd M, Richter A, Best A, Cumley N, Mirza J, Percival B, et al. S-variant SARS-CoV-2 lineage B.1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR. *J Infect Dis* [Internet]. 2021 Feb 13 [cited 2021 Apr 16];(jiab082). Available from: <https://doi.org/10.1093/infdis/jiab082>
10. Calistri P, Amato L, Puglia I, Cito F, Di Giuseppe A, Danzetta ML, et al. Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs. *Int J Infect Dis* [Internet]. 2021 Mar 5 [cited 2021 Mar 28]; Available from: <https://www.sciencedirect.com/science/article/pii/S1201971221002101>
11. Roquebert B, Haim-Boukobza S, Trombert-Paolantoni S, Lecorche E, Verdurme L, Foulongne V, et al. SARS-CoV-2 variants of concern are associated with lower RT-PCR amplification cycles between January and March 2021 in France. *medRxiv*. 2021 Mar 22;2021.03.19.21253971.
12. Teyssou E, Soulie C, Visseaux B, Lambert-Niclot S, Ferre V, Marot S, et al. The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical

variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. medRxiv. 2021 Mar 26;2021.03.21.21253498.


13. Kissler SM, Fauver JR, Mack C, Tai CG, Breban MI, Watkins AE, et al. Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2. medRxiv. 2021 Feb 19;2021.02.16.21251535.
14. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature*. 2021 Apr;592(7854):438–43.
15. Vaida F, Liu L. Fast Implementation for Normal Mixed Effects Models With Censored Response. *J Comput Graph Stat*. 2009 Jan 1;18(4):797–817.
16. SPF. COVID-19 : point épidémiologique du 18 mars 2021 [Internet]. [cited 2021 Apr 17]. Available from: /maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-epidemiologique-du-18-mars-2021
17. Marks M, Millat-Martinez P, Ouchi D, Roberts C h, Alemany A, Corbacho-Monné M, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. *Lancet Infect Dis* [Internet]. 2021 Feb 2 [cited 2021 Apr 12]; Available from: <https://www.sciencedirect.com/science/article/pii/S1473309920309853>

Strain	N	Sex		Age category										Time from symptom onset (days)					Number of tests		
		Female	Male	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80-89	≥ 90	< 0	[0, 2[	[2, 6[	[6, 12[	≥ 12	1	2	≥ 3
Historical	3272	54.3	45.7	1.65	9.32	19.5	21.2	20.2	15.8	7.21	3.51	1.41	0.183	3.18	55.9	13.4	14.3	13.2	52.7	30	17.4
B.1.351	1366	54.9	45.1	1.61	11.6	20	23.2	20.7	13.9	5.56	2.49	0.586	0.366	3.59	59.2	12.6	14.6	10.1	54.4	32.2	13.4
B.1.1.7	11496	55.3	44.7	1.85	11.4	19.6	21.5	20.6	14.6	6.6	3.01	0.6	0.27	1.87	66.8	12	11.6	7.79	67.5	24.5	7.97


**Table 1:** Overview of the test data: number of tests, and percentages of each sex, age category, time from symptom onset category, and number of tests per individual for historical strains and, B.1.351 and B.1.1.7 variants.



**Figure 1:** Ct value as a function of time since symptom onset for historical variants, suspected B.1.351 and suspected B.1.1.7. A. Ct value as a function of time since symptom onset categories in the data. B. Prediction of the linear model, with confidence intervals as shaded regions. C. Distribution of the time from symptom onset to thresholds Ct = 31 and Ct = 36 for each variant, as predicted by the linear model. This is the cumulative distribution function of the normal distribution whose mean is the predicted mean time to each threshold for each variant, and standard deviation the standard deviation of the random effect representing the inter-individual variability ( $sd = 2.9$ ). The dashed horizontal lines show the fraction of individuals no longer shedding infectious virus 10 days after symptom onset, the recommended duration of self-isolation in April 2021 in France.



**Supplementary Figure 1:** Flow chart of the data cleaning. We retained all individuals with at least one positive nasopharyngeal swab ( $N = 93,234$ ). A positive test was defined as a test with at least one PCR with a cycle threshold (Ct) value below 36 (recommendation of the *Société Française de Microbiologie*). We retained all individuals with present information on sex, age, variant, PCR method and, for individuals with multiple tests, we retained only those who had consistent information on sex, age, or variant at these tests ( $N = 63,896$ ). We retained all tests with non-missing Ct value on the RdRp gene (the most sensitive assay), all done with the Eurobio EBX-041 method (EurobioPlex SARS-CoV-2-Multiplex), and all tests at or after the first positive test ( $N = 41,489$ ). Finally, we retained all individuals with consistent time from first symptoms data ( $N = 16,134$ ); some of the individuals with multiple tests had a set of self-reported symptom dates not compatible with a unique date of symptom onset, as explained in more details below.



**Supplementary Figure 2:** Ct value as a function of time since symptom onset for historical variants, suspected B.1.351 and suspected B.1.1.7 for the Ct value of the PCR targeting the N gene. Left panel, prediction of the linear model, with confidence intervals as shaded regions. Right panel, distribution of the time from symptom onset to thresholds Ct = 31 and Ct = 36 for each variant, as predicted by the linear model. This is the cumulative distribution function of the normal distribution whose mean is the predicted mean time to each threshold for each variant, and standard deviation the standard deviation of the random effect representing the inter-individual variability ( $sd = 4.6$ ). The dashed horizontal lines show the fraction of individuals no longer shedding infectious virus 10 days after symptom onset, the recommended duration of self-isolation in April 2021 in France.

Names	Effect	[95 % CI]	p-value
Intercept	22.7	[22.4; 23]	-
Time since symptom onset	0.971	[0.926; 1.02]	< 1e-16
Variant B.1.351	-1.15	[-1.57; -0.697]	< 1e-16
Variant B.1.1.7	-1.33	[-1.59; -1.07]	
Age [0-9]	1.76	[0.982; 2.54]	< 1e-16
Age 10-19	0.704	[0.338; 1.11]	
Age 20-29	0.285	[-0.0114; 0.601]	
Age 30-39	0.309	[0.0181; 0.619]	
Age 50-59	-0.308	[-0.635; 0.0189]	
Age 60-69	-0.0862	[-0.537; 0.359]	
Age 70-79	-0.395	[-0.944; 0.226]	
Age 80-89	-0.848	[-2.08; 0.33]	
Age 90+	0.254	[-1.8; 2.24]	
Time × Variant B.1.351	0.0952	[0.0184; 0.157]	
Time × Variant B.1.1.7	0.0602	[0.0147; 0.1]	
Time × Age 0-9	-0.16	[-0.306; -0.00743]	1.76e-11
Time × Age 10-19	0.0443	[-0.0313; 0.114]	
Time × Age 20-29	0.0818	[0.0242; 0.133]	
Time × Age 30-39	-0.0092	[-0.0618; 0.0428]	
Time × Age 50-59	0.00329	[-0.0619; 0.0618]	
Time × Age 60-69	-0.129	[-0.2; -0.056]	
Time × Age 70-79	-0.222	[-0.317; -0.137]	
Time × Age 80-89	-0.226	[-0.434; -0.0287]	
Time × Age 90+	-0.431	[-0.735; -0.0897]	

**Supplementary Table 1:** Estimated fixed effects on Ct values (negatively correlated with viral load), 95% confidence intervals, and p-values, for the main model. Time is in days since symptom onset. For variants, the reference category is historical variants; for age, the reference category is age 40 to 49.

Names	Effect	[95 % CI]	p-value
Intercept	24.4	[24; 24.7]	-
Time since symptom onset	0.786	[0.733; 0.835]	< 1e-16
Variant B.1.351	-1.81	[-2.32; -1.32]	< 1e-16
Variant B.1.1.7	-2.11	[-2.38; -1.81]	
Age [0-9]	1.47	[0.487; 2.27]	1e-11
Age 10-19	0.944	[0.491; 1.35]	
Age 20-29	0.199	[-0.166; 0.565]	
Age 30-39	0.378	[0.0214; 0.753]	
Age 50-59	-0.201	[-0.584; 0.21]	
Age 60-69	-0.177	[-0.631; 0.314]	
Age 70-79	-0.186	[-0.965; 0.513]	
Age 80-89	-0.263	[-1.53; 0.997]	
Age 90+	1.37	[-0.704; 3.92]	
Time x Variant B.1.351	0.268	[0.197; 0.333]	
Time x Variant B.1.1.7	0.157	[0.117; 0.196]	
Time x Age 0-9	-0.0879	[-0.239; 0.102]	0.0005
Time x Age 10-19	-0.00847	[-0.0775; 0.0644]	
Time x Age 20-29	0.0675	[0.0127; 0.12]	
Time x Age 30-39	-0.00466	[-0.0587; 0.0496]	
Time x Age 50-59	-0.00706	[-0.0696; 0.0566]	
Time x Age 60-69	-0.0962	[-0.177; -0.0241]	
Time x Age 70-79	-0.0934	[-0.199; 0.0183]	
Time x Age 80-89	-0.157	[-0.358; 0.0262]	
Time x Age 90+	-0.218	[-0.636; 0.144]	

**Supplementary Table 2:** Estimated fixed effects on Ct values (negatively correlated with viral load), 95% confidence intervals, and p-values, for the main model applied to the Ct value of the PCR targeting the N gene instead of the RdRp gene. Time is in days since symptom onset. For variants, the reference category is historical variants; for age, the reference category is age 40 to 49.



Names	Effect	[95 % CI]
Intercept	25.5	[25.3; 25.7]
Time since first positive	1.19	[1.15; 1.23]
Variant B.1.351	-1.41	[-1.63; -1.16]
Variant B.1.1.7	-1.17	[-1.32; -1.03]
Age [0-9]	1.85	[1.58; 2.14]
Age 10-19	0.793	[0.618; 0.997]
Age 20-29	0.343	[0.165; 0.526]
Age 30-39	0.147	[-0.0437; 0.314]
Age 50-59	-0.375	[-0.569; -0.192]
Age 60-69	-0.595	[-0.836; -0.366]
Age 70-79	-0.526	[-0.823; -0.201]
Age 80-89	-0.782	[-1.16; -0.383]
Age 90+	-1.04	[-1.63; -0.426]
Asymptomatic then sympt.	-0.627	[-0.853; -0.406]
Symptomatic then asympt.	-0.319	[-0.539; -0.105]
Symptomatic	-0.951	[-1.08; -0.833]
Symptoms unknown	0.633	[-0.272; 1.68]
Time × Variant B.1.351	0.0974	[0.042; 0.158]
Time × Variant B.1.1.7	0.0464	[0.0152; 0.0782]
Time × Age 0-9	0.321	[0.201; 0.432]
Time × Age 10-19	0.035	[-0.0236; 0.0894]
Time × Age 20-29	0.0449	[-0.00734; 0.0936]
Time × Age 30-39	0.05	[-0.00637; 0.102]
Time × Age 50-59	-0.0813	[-0.131; -0.031]
Time × Age 60-69	-0.108	[-0.171; -0.0485]
Time × Age 70-79	-0.344	[-0.413; -0.275]
Time × Age 80-89	-0.483	[-0.559; -0.414]
Time × Age 90+	-0.284	[-0.415; -0.149]

**Supplementary Table 3:** Estimated fixed effects on Ct values (negatively correlated with viral load), 95% confidence intervals for the regression model on the more complete dataset (41,489 tests representing 33,391 individuals). Time is in days since first positive test instead of time since symptom onset. For variants, the reference category is historical variants; for age, the reference category is age 40 to 49.